2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5642 Exposure–Response analyses of venetoclax plasma concentration and TLS laboratory changes during venetoclax initiation in previously untreated patients with chronic lymphocytic leukemia: VENETIAN study

Aneeq Farooq, PhD, Levi Hooper, PhD, PharmD2, Insa Winzenborg, PhD3, Sama Alaei, PharmD, PhD4, Weize Huang, PharmD, PhD5, Jeff Sharman, MD6, Nilanjan Ghosh, MD7, Jacqueline Hilger-Rolfe, MD8, Jalaja Potluri, MD9, Jiuhong Zha, PhD10, Rajeev Menon, PhD11
1 AbbVie Deutschland GmbH Co. KG, Ludwigshafen am Rhein, Germany
2 AbbVie Inc., North Chicago, Illinois, United States
3 AbbVie Deutschland GmbH Co. KG, Ludwigshafen am Rhein, Germany
4 AbbVie Inc., North Chicago, Illinois, United States
5 Genentech Inc, South San Francisco, California, United States
6 Willamette Valley Cancer Institute, Eugene, Oregon, United States
7 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
8 AbbVie Inc., North Chicago, Illinois, United States
9 AbbVie Inc., North Chicago, Illinois, United States
10 AbbVie Inc., North Chicago, Illinois, United States
11 AbbVie Inc., North Chicago, Illinois, United States

Background 

Early phase 1 studies of venetoclax (Ven) in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), identified tumor lysis syndrome (TLS) as closely linked to high initial Ven doses, renal impairment, and elevated tumor burden. Transient metabolic changes were observed shortly after dosing, supporting a gradual Ven dose ramp-up strategy alongside early repeated post-dose laboratory (lab) monitoring. However, contemporary frontline regimens incorporate effective debulking with CD20 monoclonal antibodies (e.g. obinutuzumab) or Bruton tyrosine kinase inhibitors (BTKi) (e.g. acalabrutinib) prior to Ven initiation, thereby reducing the frequency and risk of TLS. Whether an exposure–response (E–R) relationship between Ven plasma concentrations (Cp) and TLS lab changes exist in this post debulked setting has not been evaluated.

Objectives 

To characterize the E–R relationship between Ven Cp and TLS-associated lab changes in previously untreated CLL patients after effective debulking, using exploratory concentration-quartile analyses and linear mixed-effects (LME) modeling.

Methods 

The VENETIAN study (NCT06428019) is a prospective open-label, global, Phase 2 study assessing TLS risk with Ven treatment in combination with obinutuzumab (Obi) or acalabrutinib (Acala) using different ramp-up schedules in first-line CLL/SLL. Data from Part 1 of the study (N=170) were analyzed. Subjects were randomized 1:1:1:1 to four arms: Arm A (Ven + Obi, 5-week ramp-up), Arm B (Ven + Acala, 5-week ramp-up) per label and exploratory Arm C (Ven + Acala, 6-week ramp-up) and Arm D (venetoclax + Acala, 7-week ramp-up). E–R analyses included patients who completed debulking, received Ven, and had paired pharmacokinetic (PK) and TLS lab samples during ramp-up.

Quartile analyses examined TLS lab abnormalities per Howard Criteria (HC) and change from post-debulking baseline (CFB) across quartiles of observed Ven Cp at matched PK–TLS timepoints. For E–R analysis, LME models were fitted to 1052-1230 paired PK–TLS observations per analyte (N=153-163), with observed Cp as the primary exposure predictor and CFB for each of the five TLS-relevant lab analytes (potassium, albumin-corrected calcium, urate, phosphorus, creatinine) as the response variable. Prior to modeling, observations were pooled from all protocol-specified lab monitoring windows including pre-dose, 6-8 h, and 24 h post-dose. Three candidate model forms were evaluated — linear Cp–response and log-linear Cp–response with inter-individual variability (IIV) on intercept, and log-linear Cp–response with IIV on both intercept and slope. Model selection was based on the Bayesian Information Criterion (BIC). Six pre-specified covariates were evaluated for effects on both intercept (additive) and slope (interaction with Cp) parameters: ramp-up week, creatinine clearance (CrCL), tumor burden at screening and post-debulking, post-debulking baseline TLS lab value, and debulking agent.

Results 

Concentration-quartile analyses showed no correlation between Ven Cp and any TLS lab abnormalities per HC or CFB in any analyte or arm. LME modeling identified no significant E–R relationship between observed Ven Cp and CFB in any of the five analytes across all protocol-specified monitoring timepoints. Accordingly, increasing Ven concentrations did not drive TLS lab values toward clinically concerning levels. Covariate analysis identified post-debulking pre dose lab values as the dominant, consistent drivers of the magnitude of TLS lab CFB across all five analytes (ΔBIC: −13.0 to −112.7). In contrast, CrCL, tumor burden at screening, and tumor burden at ramp-up initiation were not significant predictors in any LME model.

Conclusions 

Across quartile analyses and LME E–R modeling in 153-163 patients spanning four study arms, two monitoring windows, and five TLS analytes, no clinically meaningful pharmacological relationship was identified between Ven Cp and TLS lab changes following effective debulking. Post-debulking baseline lab values, not Ven exposure, were the primary determinants of TLS lab CFB. These analyses support that, in debulked CLL/SLL patients receiving TLS prophylaxis per protocol, post-dose TLS lab monitoring during ramp-up may be most effectively guided by individual patient characteristics, allowing clinicians to tailor monitoring intensity to each patient's risk profile rather than applying uniform routine assessments.

Jacqueline Hilger-Rolfe, MD: AbbVie - Current equity holder in publicly-traded company